NEW YORK (GenomeWeb News) – Insight Genetics today announced an exclusive, worldwide licensing deal with St. Jude Children's Research Hospital for a genetic test to improve donor matching in bone marrow transplants.
After being sued by Myriad Genetics for allegedly infringing its patents on BRCA1 and BRCA2 gene mutation testing, Ambry Genetics pushed back this week with its own countersuit accusing Myriad of antitrust violations.
The appeals court decided that isolated gene sequences do not occur naturally and are therefore patentable, but invalidated Myriad's method claims that describe "comparing" or "analyzing" DNA sequences, deeming them abstract, mental steps.
Diagnostic developers and legal experts have been keeping a close watch on Prometheus since the Federal Circuit Court of Appeals' handling of diagnostic method patents in that case may impact the AMP v. USPTO gene-patenting lawsuit that is pending review by the same court.
In a filing with the federal appeals court, the DoJ attempted to strike a balance between rewarding inventions that result from genomic discoveries and ensuring that discoveries of natural phenomena remain in the "storehouse of knowledge of all men." Meanwhile, it's business as usual at the USPTO until the appeals court rules on Myriad's challenged BRCA patents.
The Association of Biomolecular Resource Facilities' Nucleic Acid Research Group this week presented the results of a 2009-2010 study that assessed the impact of various priming strategies on generating cDNA for use with quantitative PCR.